$NNVC News

NanoViricides Gets National Ethics Committee Approval For Phase II Clinical Study Of NV-387 Oral Gummies To Treat Current Bundibugyo Ebolavirus In Congo

Noble Capital Markets Initiates Coverage On Nanoviricides with Outperform Rating, Announces Price Target of $6

NanoViricides Continues To Advance Broad-Spectrum Antiviral Drug NV-387 Towards Phase II Clinical Trial Of NV-387 Oral Gummies Formulation As Treatment For Current Bundibugyo Ebolavirus In DRC

US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher

FDA's Office Of Orphan Products Development Grants Rare Pediatric Disease Drug Designation To NanoViricides' Antiviral Drug NV-387

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo

NanoViricides Ships NV-387 Oral Gummies To The Democratic Republic of Congo Ahead Of Patient Enrollment For Its Phase II Clinical Trial Of Monkeypox Treatment

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo

NanoViricides' Proposal To Perform Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus Approved By Pillar Committee In Charge In DR Congo

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies

NanoViricides Proposes Phase II Clinical Study Of NV-387 Oral Gummies To Congo To Treat Current Bundibugyo Ebolavirus

NanoViricides Files Prospectus For Offering $50M Mixed Shelf

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides

NanoViricides closes $2M direct offering

NanoViricides Announces Closing of ~$2 Million Registered Direct Offering

NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak

Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides

NanoViricides to raise $2M in registered direct offering

NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering

NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II